abbviee having a 96% cure rate of hep c compared to our 90%, but one has to take into account that abbviee's candidate only does geno type 1.... ours does 1/4/5/6, so we treat a larger population and get great results!!!!
This is called profit locking after successful run, you are nut.
All Bio stocks were down 4-5%, using AMGN as excuse for profit taking.
there is huge market for HCV, take HIV drugs, statins as example, multiple players,
however first mover has huge adv. , so Gilead looks like winner